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ABSTRACT
Methods: This prospective interventional study was conducted in type 2 diabetes mellitus patients with a sample size of 100. These patients were 
diagnosed with depression using WHO-ICD10 criteria. All study patients had uncontrolled blood glucose levels and were on an optimized maximal 
dose of combination oral hypoglycemic agents with stable glycoregulation (HbA1c 8.4 ±0.5) were taken up for the intervention with antidepressant. 
These patients were started on with antidepressant after enrollment and followed up for fasting blood sugar (FBS), post-prandial blood sugar (PPBS), 
and HbA1c at the end of 3 months and 6 months. And also Hamilton depression rating scale scores were estimated at the beginning of the study and 
at the end of 6 months.
Results: The frequency of depression among the type 2 diabetes mellitus patients was found to be 42%. There were reduction of mean FBS levels from 
baseline value of 177 mg/dl to follow-up value of 160 mg/dl (p<0.001), mean PPBS levels from 251.16 mg/dl to 217.84 mg/dl (p<0.001), and mean 
HbA1c dropped from 8.41 to 7.57 (p<0.001) after the treatment with antidepressant.
Conclusion: Our study concluded that patient started on antidepressant showed a reduction in the blood sugar levels and HbA1c levels from their 
baseline values, which was clinically and statistically significant.
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BACKGROUND
Globally, diabetes mellitus is one of the most serious chronic illnesses due 
to its negative effect on the quality of life of the affected individuals [1]. 
Nearly 422 million adults had diabetes mellitus according to the 2016 
data from the World Health Organization (WHO) and its prevalence 
is expected to increase to 552 million by 2030 [2]. In India, there are 
62.4 million people with type 2 diabetes mellitus and 77 million people 
with pre-diabetes according to the recent report by Indian Council of 
Medical Research–India Diabetes national study and these numbers are 
estimated to rise to 101 million by 2030 [3].
Depression incidence is higher in diabetic patients when compared to the 
non-diabetic individuals and there exist a two-directional relationship 
between depression and the development of type 2 diabetes mellitus [4]. 
The two main currently existing hypotheses explain the causal pathway 
between depression and the occurrence of diabetes. The first hypothesis 
showed that depression increases the risk of developing diabetes. The 
associated chronic stress in depression leads to hypercortisolemia and it 
may cause centripetal obesity and metabolic syndrome. The physiological 
alterations like rising in levels of glucocorticoids, catecholamines, growth 
hormones, modification in the glucose transport function, and secretion 
of inflammatory cytokines in depression contribute to insulin resistance 
and abnormal beta islet cell functioning and ultimately become the causal 
factors for the development of diabetes as well as its complications. 
The second hypothesis states that psychosocial stressors of having a 
chronic medical condition (type 1 and type 2 diabetes mellitus) lead 
to depression [5]. Depression results in increased medical utilization 
and costs, symptom burden, increased functional impairment, non-
compliance to treatment, decrements in quality of life, and increased rates 
of mortality [6-8]. The rise in the diabetic population in our country and 
the existence of a significant causative connection between depression 
and poor glycemic control necessitate the need for studying the effect of 
antidepressant use on glycemic control of diabetes patients.
Recent studies have shown that short-term administration of tricyclic 
antidepressants (TCAs) such as nortriptyline and imipramine may end in 
reduced fasting blood glucose, but extended use raises the baseline values 
because of their catecholamine profile. Thus, TCAs can be used for the 
effective management of depression but it can also lead to deterioration 
of glucose control [9]. The other class of antidepressant studied was 
selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, 
sertraline, and escitalopram. Apart from the reduction in the severity of 
depression these drugs can also improve both compliance and glycated 
hemoglobin (HbA1c) levels [10]. Thus, this study aimed to determine the 
frequency of depression among the type 2 diabetes patients and also to 
assess the effect of antidepressant on glycemic control.
METHODS
This prospective observational study was conducted in the Department 
of General Medicine from November 2016 to September 2018 after 
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approval from the Institutional Human Ethical Committee of JSS 
Medical College and Hospital, Mysore, Karnataka.
Study Criteria
Diabetic patients aged more than or equal to 18 years who were free 
from chronic debilitating conditions and receiving a maximal dose of 
the combination oral hypoglycemic agents (OHAs) were included in 
the study after obtaining informed consent from the patients. Patients 
were excluded from the study if they were on insulin therapy, type 1 
diabetic patients, age was more than 60 years of age, diabetes patients 
having a history of prior psychiatric illness, and/or prior treatment 
with psychiatric medicines and the patients who were not willing to 
give the informed consent.
Study procedure
All diabetic patients attending the general medicine outpatient 
department of the study hospital during the study period who fulfilled 
the inclusion criteria were enrolled after obtaining informed consent. 
The enrolled patients were screened for depression using patient 
health questionnaire and Hamilton depression rating scale (HAM-D) 
criteria and thereby diagnosed for depression using WHO-ICD 10 
criteria. The patients diagnosed with moderate to severe depression 
and were having uncontrolled blood glucose levels and on an optimized 
maximal dose of combination OHAs with stable glycoregulation (HbA1c 
8.4 ±0.5) were taken up for the intervention with antidepressant tablet 
escitalopram.
The dose of the antidepressant in each individual patient was titrated 
to the optimal dose range by the psychiatrist and clinical pharmacist 
during the treatment course. All antidiabetic medications were kept at 
the same dose and regimen during the study period. Patients started on 
antidepressant were followed up twice at the end of 3 months and at 6 
months. FBS, PPBS, and HbA1c (FBS and PPBS were measured by glucose 
oxidase method and HbA1C was estimated by HPLC) were estimated at 
the beginning of the study and at the follow-up. HAM-D scores were 
estimated at the beginning of the study and at the end of 6 months.
RESULTS
A total of 252 type 2 diabetic patients were screened, of which 
100 patients fulfilled the inclusion criteria and were screened for 
depression. Frequency of depression among the type 2 diabetics was 
found to be 42%. Among depressed patients, 21 (50%) were in the age 
group of 51–60 years, 18 (42.9%) were in the age group of 41–50 years, 
and 3 (7.1%) were in the age group of <40 years (Table 1). Among the 
depressed patients, there was female preponderance with 25 patients 
(59.5%) being female and 17 patients (40.4%) being male. This data 
were in line with most major epidemiological studies which reported 
higher prevalence rates for depression among females and older age 
groups (Table 2). The duration of diabetes among the depressed was 
7.8±3.3 years. About 77% of the diabetic patients were depressed with 
duration more than 10 years which showed that as the duration of 
diabetes increases, there is an increased risk of developing depression 
(Table 3).
Interventional effect of antidepressant on fasting blood sugar 
(FBS), post-prandial blood sugar (PPBS), and HbA1c levels
There was reduction of mean FBS, PPBS, and HbA1c levels from baseline 
value of 177 mg/dl, 251.16 mg/dl, and 8.41% to follow-up value of 
160 mg/dl (p<0.001), 217.84 mg/dl (p<0.001), and 7.57 (p<0.001), 
respectively (Table 4).
Interventional effect of antidepressant on depression status
Improvement in depression status by antidepressant therapy was 
confirmed by the significant decrease of HAM-D scores from 17.3±2.5 
to 14.4±2.8 (p=0.0001) over the interventional phase (Fig. 1).
Interventional effect of antidepressant: Association between 
improvement in depression status and improvement in glycemic 
control
Association and directional nature between changes in depression and 
diabetes status were addressed by checking the relationship between 
the change of HAM-D score (delta HAM-D) and the change in HbA1c 
levels (delta HbA1c) during the interventional phase by means of 
Pearson’s correlation testing. A positive linear correlation between 
improvement in depression scale and improvement in glycemic control 
was observed, with corresponding p=0.015 (Fig. 2).
DISCUSSION
Frequency of depression among type 2 diabetes mellitus
In this study, the frequency of depression among type 2 diabetes 
patients was found to be 42%. Among the study patients, 71.42% were 
Table 2: Gender distribution among diabetic patients with and without depression
Age category Diabetic patients without depression
Female Male Total
Count Column n % Count Column n % Count Column n %
<40 6 12.8 13 24.5 19 19
41–50 20 42.6 21 39.6 41 41
51–60 21 44.7 19 35.8 40 40
Total 47 100 53 100 100 100
Age category Diabetic patients with depression
Female Male Total
Count Column n % Count Column n % Count Column n %
<40 1 4 2 11.8 3 7.1
41–50 11 44 7 41.2 18 42.9
51–60 13 52 8 47.1 21 50
Total 25 100 17 100 42 100






Count Column n % Count Column n %
<40 16 27.6 3 7.1
41–50 23 39.7 18 42.9
51–60 19 32.8 21 50.0
Total 58 100.0 42 100.0
p=0.03, Chi-square test
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Age and sex distribution
In our study, among depressed patients 21(50%) were in the age group 
51–60 years. There was a female preponderance among depressed 
patients with 25 patients (59.5%) being female and 17 patients (40.4%) 
being male. In Mushtaque et al. study, the mean age of the depressed 
group was 50.90±7.73 years and that of the non-depressed group 
was 48.88±9.54 years. The difference in the age of both groups was 
not statistically significant (t=0.993, p=0.301). Although depression 
was more prevalent in the female age group, gender was not found 
to be significantly associated with depression (p=0.920) [12]. In a 
systematic review and meta-analysis by Ali et al. designed to estimate 
the prevalence of clinically depressed patients with type 2 diabetes, 
found that the prevalence of depression was significantly higher 
among patients with type 2 diabetes (17.6%) than those without 
diabetes (9.8%). They also found that the prevalence among females 
with diabetes (23.8%) was higher than their male counterparts with 
diabetes (12.8%) [13]. In most of the studies, socio-demographic 
factors of age and gender did not seem to have any significant influence 
on the occurrence of depression, neither did the duration of diabetes.
Improvement of glycemic control during the treatment for 
depression
Our study showed a beneficial effect of antidepressant on glycemic 
control beyond standard diabetic treatment practice. There was 
reduction of mean FBS levels from baseline value of 177 mg/dl to 
follow-up value of 160 mg/dl (p<0.001), mean PPBS levels from 
baseline value of 251.16 mg/dl to follow-up value of 217.84 mg/dl 
(p<0.001) and mean HbA1c dropped from 8.41 to 7.57 (p<0.001). In 
Nicolau et al. study, 48 type 2 diabetes patients treated with citalopram 
were screened for determining its effect on depressive symptoms and 
metabolic control. Patients were followed for 6 months. There were 
significant improvement in depression scores and in almost all areas 
of the quality of life; however, no differences were found in glycemic 
control assessed by HbA1c [14]. Dhavale et al. study investigated the 
effect of escitalopram in 100 type 2 diabetes mellitus with increased 
blood glucose levels. Depressed patients were then started on 
escitalopram while their diabetes treatment remained unchanged. They 
were reviewed 6 weeks later and blood glucose levels were repeated. 
At the follow-up, 47% of patients started on escitalopram showed 
clinically and statistically significant lower fasting and postprandial 
blood glucose levels [9].
Finally, bearing in mind the results of our study, as well as the data from 
other publications that we have reviewed and believed that further 
investigations in this field are needed to produce definitive results on 
Table 4: Baseline FBS, PPBS, and HbA1c levels among the 
depressed and effect of antidepressant on FBS, PPBS, and HbA1c 
levels
FBS value Mean Standard deviation p value
Baseline 177.00 7.44 (p<0.001)
At 3 months 169.74 8.02
At 6 months 160.03 12.78
PPBS value
Baseline 251.16 8.49 (p<0.001)
At 3 months 237.11 14.54
At 6 months 217.84 25.53
HbA1c value
Baseline 8.41 0.50 (p<0.001)
At 3 months 8.02 0.39
At 6 months 7.57 0.47
p<0.001, each point, <0.0001, repeated measure ANOVA. FBS: Fasting blood 
sugar, PPBS: Post-prandial blood sugar, HbA1c: Glycated hemoglobin






Count Row n % Count Row n %
<5 year 32 76.2 10 23.8
6–10 year 24 49.0 25 51.0
>10 year 2 22.2 7 77.8
p=0.002, Chi-square test
moderately depressed and 28.5% were severely depressed. Das et al. 
study showed the rate of major depressive disorder to be 46.15% in 
type 2 diabetes mellitus and among them 32.2% were mildly depressed, 
36.7% were moderately depressed, 14.4% had severe depression 
(n=13), and 16.7% had very severe depression according to the HAM-D 
scale [11]. Mushtaque et al. study revealed that there were a total of 
38.75% type 2 diabetes mellitus patients suffered from depression. Out 
of them, the majority were moderately depressed (48.38%) and none 
were found to be suffering from very severe depression by HAM-D 
scoring [12]. Overall, our findings were comparable with most of the 
studies showing an increased prevalence of depression among type 2 
diabetics which needs to be screened for depression.
Fig. 1: Mean baseline and follow-up values of Hamilton 
depression rating scale scores
Fig. 2: Correlation between delta Hamilton depression rating 
scale and delta HbA1c
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the significance and range of psychiatric treatment in patients with 
diabetes and comorbid depression, including the development of more 
comprehensive and collaborative models for treating both depression 
and diabetes.
Association between changes in depression status and glycemic 
control
Our study reports a linear association between improvement in 
HAM-D scores (delta HAM-D) and improvement in HbA1c values 
(DHbA1c) in diabetic patients with comorbid depression treated 
with SSRI antidepressant. It indicates the reciprocal interaction 
between depression and glycoregulation, suggesting that treatment 
of depression may be beneficial to both mood and glycemic control. 
Wiltink et al. study showed a linear and consistent association to the 
intensity of depression in the presence of diabetes (increasing from 
6.9% in no or minimal depression to 7.6% in mild, 9% in moderate, 
and 10.5% in severe depression), i.e., the prevalence of diabetes was 
elevated substantially (1.5 fold) in severe versus non-depressed 
patients [15].
LIMITATIONS
Our study did not include a control group because it would mean 
deterring psychiatric consultation and consecutive treatment in 
patients with a high HAM-D score corresponding to moderate to severe 
depression.
CONCLUSION 
Our study concluded that patients started on antidepressant showed 
a reduction in the blood sugar levels and HbA1c levels from their 
baseline values, which was clinically and statistically significant. This 
underscores the need for screening and treatment of depression in 
patients with diabetes, particularly so if the duration of diabetes is 10 
years and beyond.
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